China's Burning Rock Biotech Q4 net loss narrows as costs fall

Burning Rock Biotech

12/03/2026 11:15

Overview

China precision oncology firm's Q4 revenue was stable year-over-year at RMB126.3 mln

Gross profit and gross margin rose, supported by lower costs and higher-margin mix

Net loss narrowed sharply on lower operating expenses from cost controls and headcount reduction

Outlook

Company did not provide specific guidance for future periods

Result Drivers

CENTRAL LAB GROWTH - Revenue from central laboratory business rose 12.1% on higher CanCatch test volumes

IN-HOSPITAL EXPANSION - In-hospital business revenue rose 17.3% due to increased sales volume from existing and new partner hospitals

PHARMA SERVICES DECLINE - Pharma R&D services revenue fell 27.7% due to decreased testing services for pharma customers from timing of lumpy projects

Company press release: ID:nGNX6VPFB4

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
RMB 126.30 mln
Q4 Net Income
-RMB 15.40 mln
Q4 Adjusted Gross Margin
80.30%
Q4 Gross Profit
RMB 98.60 mln
Q4 Operating Expenses
RMB 110.60 mln


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)